1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Real-World Outcome Analysis of Continuously and Intermittently Treated Patients with Moderate to Severe Psoriasis after Switching to a Biologic Agent.
(
- Contribution to journal › Article
- 2013
-
Mark
Validation of a Parental Questionnaire to Identify Atopic Dermatitis in a Population-Based Sample of Children up to 2 Years of Age.
(
- Contribution to journal › Article
- 2012
-
Mark
Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice
(
- Contribution to journal › Article
- 2010
-
Mark
Design and Feasibility of an International Study Assessing the Prevalence of Contact Allergy to Fragrances in the General Population: The European Dermato-Epidemiology Network Fragrance Study
(
- Contribution to journal › Article
- 2009
-
Mark
New Findings in PiZZ alpha(1)-Antitrypsin Deficiency-Related Panniculitis Demonstration of Skin Polymers and High Dosing Requirements of Intravenous Augmentation Therapy
(
- Contribution to journal › Article
- 2006
-
Mark
Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet (R)/Dovobet (R)/Taclonex (R)) in the treatment of psoriasis vulgaris
(
- Contribution to journal › Article
-
Mark
Uppdate on the activities of the European Dermato-Epidemiology Network (EDEN)
(
- Contribution to journal › Article